MMED:CC News and Press, MIND MEDICINE INC. From 06/30/22

MindMed Announces Completion of Share Redesignation Canada NewsWire NEW YORK , June 30, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) ("MindMed'' or the "Company") announces that it has completed its previously announced redesignat...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a number of mental health conditions. The Tesla CEO said ...

Mindmed Announces Voting Results for Annual General and Special Meeting Canada NewsWire NEW YORK , June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's ...

MindMed to Participate in the Jefferies Global Healthcare Conference Canada NewsWire NEW YORK , June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company develo...

MindMed Appoints Schond L. Greenway as Chief Financial Officer Canada NewsWire NEW YORK , May 23, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developin...

MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal Canada NewsWire - Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing sup...

MindMed Announces At-The-Market Offering Canada NewsWire NEW YORK , May 16, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health ...

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) announced Monday its financial results for the first quarter of 2022. MindMed is a New York-based psychedelic medicine biotechnology company that develops psychedelic-inspired drugs and therapies to combat addiction and mental illn...

MindMed Reports First Quarter 2022 Financial Results and Business Highlights Canada NewsWire - Advanced clinical programs for three lead drug candidates - - Strengthened leadership team with the appointment of Francois Lilienthal , MD as Chief Commercial Of...

MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management Canada NewsWire - Webinar to feature presentations from Kelly E. Dunn , PhD, MBA, and Stuart Gitlow , MD, MPH, MBA, on Thursday, May 19 at 11:00am EDT - ...